Top

BMC Psychiatry

Published in:

Open Access 01-12-2021 | Schizophrenia | Research article

Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil

Authors: Izabela Fulone, Marcus Tolentino Silva, Luciane Cruz Lopes

Published in: BMC Psychiatry | Issue 1/2021

Abstract

Background

The use of atypical antipsychotics for the treatment of schizophrenia and other mental disorders in populations under 18 years of age is increasing worldwide. Little is known about treatment patterns and the influence of gender differences, which may be a predictor of clinical outcomes. The aim of this study was to investigate gender differences in the use of atypical antipsychotics in patients with early-onset schizophrenia (EOS) assisted by the public health system in Brazil.

Methods

We conducted a cross-sectional study of outpatients with EOS aged 10 to 17 years who received at least one provision of atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine or ziprasidone) from a large Brazilian pharmaceutical assistance programme. Data were retrieved from a nationwide administrative database from 2008 to 2017.

Results

Of the 49,943 patients with EOS, 63.5% were males, and the mean age was 13.6 years old. The patients were using risperidone (62.5%), olanzapine (19.6%), quetiapine (12.4%), ziprasidone (3.3%) and clozapine (2.2%). We found gender differences, especially in the 13–17 year age group (65.1% for males vs. 34.9% for females, p < 0.001), in the use of risperidone (72.1% for males vs. 27.9% for females, p < 0.001) and olanzapine (66.5% for males vs. 33.5% for females, p < 0.001). Only in the 13 to 17 years age group were the prescribed doses of olanzapine (p = 0.012) and quetiapine (p = 0.041) slightly higher for males than for females.

Conclusions

Our findings showed gender differences among patients diagnosed with EOS and who received atypical antipsychotics. More attention should be devoted to gender differences in research and clinical practice.

Driver DI, Thomas S, Gogtay N, Rapoport JL. Childhood-onset schizophrenia and early-onset schizophrenia Spectrum disorders: an update. Child Adolesc Psychiatr Clin N Am. 2020;29(1):71–90. https://doi.org/10.1016/j.chc.2019.08.017.CrossRefPubMed

Preda AB, Bora RG. Esquizofrenia. BMJ Best Practice. [updated on 02 August 2017]. https://bestpractice-bmj.com.libaccesslibmcmasterca/topics/en-gb/406/pdf/406pdf. Accessed 10 Nov 2017.

Gilberg C. Schizophrenia in children and adolescents. In: Remischmidt H, editor. Epidemiology of early onset schizophrenia. Cambridge: Cambridge University Press; 2001. p. 43–59.

Okkels N, Vernal DL, Jensen SO, McGrath JJ, Nielsen RE. Changes in the diagnosed incidence of early onset schizophrenia over four decades. Acta Psychiatr Scand. 2013;127(1):62–8. https://doi.org/10.1111/j.1600-0447.2012.01913.x.CrossRefPubMed

Thomsen PH. Schizophrenia with childhood and adolescent onset: a nationwide register-based study. Acta Psychiatr Scand. 1996;94(3):187–93. https://doi.org/10.1111/j.1600-0447.1996.tb09847.x.CrossRefPubMed

Takahashi S, Matsuura M, Tanabe E, Yara K, Nonaka K, Fukura Y, et al. Age at onset of schizophrenia: gender differences and influence of temporal socioeconomic change. Psychiatry Clin Neurosci. 2000;54(2):153–6. https://doi.org/10.1046/j.1440-1819.2000.00651.x.

Hsu CW, Lee SY, Wang LJ. Gender differences in the prevalence, comorbidities and antipsychotic prescription of early-onset schizophrenia: a nationwide population-based study in Taiwan. European child & adolescent psychiatry. 2019;28(6):759–67. https://doi.org/10.1007/s00787-018-1242-9.CrossRef

Kühl JOG, Laursen TM, Thorup A, Nordentoft M. The incidence of schizophrenia and schizophrenia spectrum disorders in Denmark in the period 2000-2012. A register-based study. Schizophr Res. 2016;176(2–3):533–9. https://doi.org/10.1016/j.schres.2016.06.023.CrossRefPubMed

National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people. 2015. https://www.ncbi.nlm.nih.gov/books/NBK552055/. Accessed 03 Nov 2020.

10.

Vyas NS, Gogtay N. Treatment of early onset schizophrenia: recent trends, challenges and future considerations. Front Psychiatr. 2012;3:29.CrossRef

11.

Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst Rev. 2007;3:Cd004027.

12.

Harvey RC, James AC, Shields GE. A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS drugs. 2016;30(1):27–39. https://doi.org/10.1007/s40263-015-0308-1.CrossRefPubMed

13.

Alves MR, Bergamaschi CC, Sorrilha FB, Fulone I, Barberato-Filho S, Mayer RCF, et al. Critical appraisal and comparison of recommendations of clinical practice guidelines for treatment of schizophrenia in children and adolescents: a methodological survey protocol. BMJ Open. 2020;10(9):e038646. https://doi.org/10.1136/bmjopen-2020-038646.

14.

Abidi S, Mian I, Garcia-Ortega I, Lecomte T, Raedler T, Jackson K, et al. Canadian guidelines for the pharmacological treatment of schizophrenia Spectrum and other psychotic disorders in children and youth. Can J Psychiatr. 2017;62(9):635–47. https://doi.org/10.1177/0706743717720197.

15.

British National Formulay (BNF) for children 2019–2020. 2019. bnfc.nice.org.uk. Acessed 03 November 2020.

16.

Klasco R. DRUGDEX System [Internet]. Greenwood Village (Colorado): Thomson Micromedex; [1974–2019]. https://wwwmicromedexsolutions-com. Acessed 03 November 2020.

17.

Curtis LH, Masselink LE, Østbye T, Hutchison S, Dans PE, Wright A, et al. Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Archives of pediatrics & adolescent medicine. 2005;159(4):362–6. https://doi.org/10.1001/archpedi.159.4.362.

18.

Bachmann CJLT, Glaeske G, Hoffmann F. Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012. Dtsch Arztebl Int. 2014;111(3):25–34. https://doi.org/10.3238/arztebl.2014.0025.CrossRefPubMedPubMedCentral

19.

BRAZIL. Indicadores básicos para a saúde no Brasil: conceitos e aplicações / Rede Interagencial de Informação para a Saúde - Ripsa. 2 ed. Brasília: Organização Pan-Americana da Saúde; 2008. p. 349. http://tabnet.datasus.gov.br/tabdata/livroidb/2ed/indicadores.pdf. Accessed 12 Nov 2019.

20.

BRAZIL. Protocolo clínico e diretrizes terapêuticas. Esquizofrenia. 2013. http://portalarquivos.saude.gov.br/images/pdf/2014/abril/02/pcdt-esquizofrenia-livro-2013.pdf. Accessed 12 November 2019.

21.

World Health Organization. WHO Collaboration Centre for Drug Statistics Methodology. https://www.whocc.no/atc_ddd_index/. Accessed 10 Nov 2020.

22.

Chen W, Cepoiu-Martin M, Stang A, Duncan D, Symonds C, Cooke L, et al. Antipsychotic prescribing and safety monitoring practices in children and youth: a population-based study in Alberta, Canada. Clinical drug investigation. 2018;38(5):449–55. https://doi.org/10.1007/s40261-018-0626-4.

23.

Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 2003;60(6):565–71. https://doi.org/10.1001/archpsyc.60.6.565.CrossRefPubMed

24.

Jerrell JM, McIntyre RS. Factors Differentiating Childhood-Onset and Adolescent-Onset Schizophrenia: A Claims Database Study. Prim Care Companion CNS Disord. 2016;2(18):10.4088/PCC.15m01901. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956428/.

25.

Angermeyer MC, Kühn L. Gender differences in age at onset of schizophrenia. An overview. Eur Arch Psychiatr Neurol Sci. 1988;237(6):351–64. https://doi.org/10.1007/BF00380979.CrossRef

26.

Li R, Ma X, Wang G, Yang J, Wang C. Why sex differences in schizophrenia? J Transl Neurosci (Beijing). 2016;1(1):37–42.

27.

Riecher-Rössler A, Butler S, Kulkarni J. Sex and gender differences in schizophrenic psychoses-a critical review. Archives of women's mental health. 2018;21(6):627–48. https://doi.org/10.1007/s00737-018-0847-9.CrossRefPubMed

28.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS. Atypical antipsychotics for psychosis in adolescents. Cochrane Database Syst Rev. 2013;10:Cd009582.

29.

BRAZIL. National Sanitary Surveillance Agency (ANVISA). Bulário eletrônico. http://www.anvisa.gov.br/datavisa/fila_bula/index.asp. Accessed 20 November 2020.

30.

Schröder C, Dörks M, Kollhorst B, Blenk T, Dittmann RW, Garbe E, et al. Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011. European child & adolescent psychiatry. 2017;26(4):413–20. https://doi.org/10.1007/s00787-016-0905-7.

31.

Dinnissen M, Dietrich A, van der Molen JH, Verhallen AM, Buiteveld Y, Jongejan S, et al. Prescribing antipsychotics in child and adolescent psychiatry: guideline adherence. European child & adolescent psychiatry. 2020;29(12):1717–27. https://doi.org/10.1007/s00787-020-01488-6.

32.

Vitiello B. Pediatric psychopharmacology and the interaction between drugs and the developing brain. Can J Psychiatr. 1998;43(6):582–4. https://doi.org/10.1177/070674379804300605.CrossRef

33.

Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2012;9:Cd008559.

34.

Thomson A, Maltezos S, Paliokosta E, Xenitidis K. Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. Cochrane Database Syst Rev. 2009;2:Cd007011.

35.

Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev. 2007;1:Cd005040.

36.

Aichhorn W, Marksteiner J, Walch T, Zernig G, Hinterhuber H, Stuppaeck C, et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol. 2007;17(5):665–74. https://doi.org/10.1089/cap.2006.0045.

37.

Usall J, Suarez D, Haro JM. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res. 2007;153(3):225–31. https://doi.org/10.1016/j.psychres.2006.09.016.CrossRefPubMed

38.

Eugene AR, Masiak J. A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy. Nordic journal of psychiatry. 2017;71(6):417–24. https://doi.org/10.1080/08039488.2017.1314011.CrossRefPubMedPubMedCentral

Title: Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil
Authors: Izabela Fulone
Marcus Tolentino Silva
Luciane Cruz Lopes
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Schizophrenia
Antipsychotics
Antipsychotics
Clozapine
Olanzapine
Quetiapine
Risperidone
Ziprasidone
Published in: BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-021-03327-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Parental bonding styles in schizophrenia, depressive and bipolar patients: a comparative study

Feeling matters: perceived social support moderates the relationship between personal relative deprivation and depressive symptoms

Efficacy of web-based self-management interventions for depressive symptoms: a meta-analysis of randomized controlled trials

Relationships of coping styles and psychological distress among patients with insomnia disorder

Increased symptoms of post-traumatic stress in school students soon after the start of the COVID-19 outbreak in China

Physical activity, post-traumatic stress disorder, and exposure to torture among asylum seekers in Sweden: a cross-sectional study